Encore Therapeutics Inc. Demonstrates Proof Of Concept For A Long-Acting Buprenorphine Depot For Pain And Drug Abuse Therapy (ETI-311)
Encore Therapeutics Inc. (ETI) today reported that ETI-311, the company’s novel long-acting depot for buprenorphine, produced clinically relevant plasma levels of the drug over 3-7 days when administered by intradermal injection in dog studies. These results add to the growing number of applications for ETI’s drug delivery platform technology to deliver drugs both locally and systemically in a high-load and continuous manner.
More: continued here